

Dr Marylène Clausse  
Born in Namur on the 26/11/1970  
INAMI number : 1-93050-77-660  
Business address : Clinique Saint-Luc  
Rue Saint-Luc, 8  
5004 Bouge (Namur)  
Tél. Secretary Daycare Hospital 081/20.91.71  
Fax. 081/20.95.37  
Email address : [marylene.clausse@slbo.be](mailto:marylene.clausse@slbo.be)

---

## **Education**

- Medical diploma, UCL, 1996
  - Licence in internal medicine, UCL, 2002
    - first year : CHBS Auvelais
    - second year : Clinique St-Luc (Bouge) – Clinique St-Joseph (Gilly)
    - third year : Cliniques Universitaires Saint-Luc. Pr Symann, medical oncology
  - Specialisation in hemato-oncology, UCL
    - fourth year : Cliniques Universitaires Saint-Luc. Pr. Symann, medical oncology
    - fifth year : Cliniques Universitaires Mont-Godinne. Pr. Bosly, hematology
  - Competence in oncology
    - sixth year : Jules Bordet Institute. Pr. Klastersky, medical oncology
  - Agreement in medical oncology obtained on 22/09/2008
- 
- 

## **Clinical experience**

- Responsible assistant of the department of General Internal Medicine at the Clinique Saint-Luc Bouge (Namur) since 10/2002
  - Supervision of the hospital in medical oncology
  - Responsible of the daycare hospital (22 lits)
  - Coordinator of the multidisciplinary oncology consultation
  - Responsible of clinical studies in oncology. Involvement in several phase III studies
  - Exclusive practice of medical oncology at full time
  
  - Certificate of Achievement GCP Training obtained on 24/04/2020 and 07/05/2022.
- 
-

## Professional affiliation

- Member of BSMO
  - Member of BGDO
  - Member of FFCD
  - Member of GLEM n° 1648 - UCL
- 
- 

## Publications

- *Lymphome T/NK périphérique à localisation nasale.*  
Louvain Médical, 2001. M Clause, A Bosly, A Sonet.
- *A Belgian registry of interleukin-2 administration for treatment of metastatic renal cell cancer and confrontation with literature data.*  
Acta Clinica Belgica 2007 Jul-Aug; 62(4):223-9. I Bambust, F Van Aelst, E Joosens, D Schallier, H Rezaei Kalantari, R Paulus, V Renard, M Clause, L Duck, S Luce, P Pierre, S Van Belle, S Rottey.
- *Carcinoid tumor of the small intestine : MDCT findings with pathologic correlation.*  
JBR-BTR, 2007, 90: 507-515. B Coulier, J Pringot, I Gielen, P Maldague, B Broze, A Ramboux, M Clause.
- *Prospective randomized study comparing docetaxel, estramustine and prednisone with docetaxel plus prednisone in metastatic hormone-refractory prostate cancer.*  
J Clin Oncol., 2008 Nov (10) ; 26 (32) : 5261-8. JP Machiels, F Mazzeo, M Clause, B Filleul, L Marcelis, B Honhon, L D'Hondt, C Dopchie, V Verschaeve, L Duck, D Verhoeven, MA Bonny, AM Moxhon, B Tombal, J Kerger.
- *Metastases of clinically occult testicular seminoma mimicking primary extragonadal retroperitoneal germ cells.* JBR-BTR, 2008, 91:0-00. B Coulier, Y Lefebvre, L de Visscher, A Bourgeois, L Montfort, M Clause, P Maillieux, I Gielen.
- *Phase I study of sorafenib in combinaison with docetaxel and prednisolone in chemo naïve patients with metastatic castration-resistant prostate cancer.*  
Cancer Chemother Pharmacy. 2012 Aug ; 70(2) : 293-303.  
F Mardjadi, J Medioni, J Kerger, L D'Hondt, JL Canon, L Duck, F Musuamba, S Oudard, M Clause, A Moxhon, JP Machiels.
- *Preoperative chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer : interim analysis of the Pepita study.*  
Acta Gastro-Enterologica Belgique. 2014 ; 77(1). A Hendlisz, A Deleporte, JL Van Laethem, P Vergauwe, M Van Den Heyde, G Deboever, J Janssens, G Demoulin, S Holbrechts, M Clause.
- *Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.*  
Urol Oncol. 2016 Jun ; 34(6) : 254. C Van Praet, S Rottey, F Van Hende, G Pelgrims, W Demey, F Van Aelst, W Wynendaele, T Gil, P Schatterman, B Filleul, D Schallier, JP Machiels, D Schrijvers, E Everaert, L D'Hondt, P Werbrouck, J Vermeij, J Mebis,

M Clause, M Rasschaert, J Van Erps, J Verheezen, J Van Haverbeke, JC Goeminne, N Lumen.

- *Which Factors Predict Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel ?*

Clin Genitourin Cancer. 2017 Aug ; 15(4) : 502-508. C Van Praet, S Rottey, F Van Hende, G Pelgrims, W Demey, F Van Aelst, W Wynendaele, T Gil, P Schatteman, B Filleul, D Schallier, JP Machiels, D Schrijvers, E Everaert, L D'Hondt, P Werbrouck, J Vermeij, J Mebis, M Clause, M Rasschaert, J Van Erps, J Verheezen, J Van Haverbeke, JC Goeminne, N Lumen.

- *Fortnightly or fractionated weekly docetaxelcisplatin-5FU as first-line treatment in advanced gastric and gastro-esophageal junction adenocarcinoma: the randomized phase II DoGE study.* A Deleporte, M Van den Eynde, F Forget, S Holbrechts, T Delaunoy, G Houbiers, H Rezaei Kalantari, S Laurent, E Vanderstraeten, M De Man, P Vergauwe, M Clause, J Van Der Auwera, L D'Hondt, P Pierre, B Ghillemin, A Covas, F Sclafani, M Paesmans, L Ameye, A Awada, A Hendlisz

- *Intralobar Pulmonary Sequestration with Rete Mirabilis as Part of Its Systemic Artery* Open Journal of Medical Imaging, 2020, 10, 89-95. P Mailleux and M Clause

---

## Oral presentations

- Congress of Clinical Biology : management of the acute myeloid leukemia in the elderly (60 years old and more), 2001. M Clause
- Palliative chemotherapy : indications and pitfalls, 05/2011
- Place of immunotherapy and hormone therapy in the oral treatment of breast cancer, 03/2016
- Dietary and lifestyle measures after breast cancer, 06/2013
- Exercice Medecine, 06/2017
- Emergencies in Clinical Oncology, 10/2018
- Cardio-Oncology in 2019, 09/2019. M Clause and H Tourmous